Capital Fund Management (CFM)
GTHX

Capital Fund Management (CFM)’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Capital Fund Management (CFM)’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,806
Closed -$229K – 1669
2020
Q1 		$229K Buy
+20,806
New +$389K ﹤0.01% 1352
2019
Q2 		– Sell
-11,600
Closed -$193K – 1988
2019
Q1 		$193K Buy
+11,600
New +$220K ﹤0.01% 1597

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Capital Fund Management (CFM)'s GTHX Position: Q2 2020 in Review

Capital Fund Management (CFM) sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2020, closing a stake of 20,806 shares — an estimated $229K sold.

Capital Fund Management (CFM) first reported a position in GTHX in Q1 2019 and held it in 2 quarters. The position peaked at $229K in Q1 2020. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

  • Capital Fund Management (CFM) reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 20,806 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $229K.
  • Capital Fund Management (CFM) first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Capital Fund Management (CFM)'s G1 Therapeutics, Inc. Common Stock position peaked at $229K in Q1 2020.
  • 100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2020, filed 13 Aug 2020.